Lenz Therapeutics, Inc. has just announced the commercial availability of Vizz (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. This is a significant development as presbyopia affects approximately 128 million adults in the United States. The product is now being distributed to eye care professionals across the country, with commercial shipments to consumers set to begin in October and expected to be broadly available, including via retail pharmacies, by mid-Q4 2025.
Vizz is differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. In the clarity phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and the effects lasted up to 10 hours. This level of near vision improvement can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses.
Lenz Therapeutics' President and CEO, Eef Schimmelpennink, expressed excitement about introducing Vizz to the 128 million adults living with blurry near vision in the United States. The company's Chief Commercial Officer, Shawn Olsson, highlighted that Vizz offers a simple, fast-acting way for people living with presbyopia to see up close again, thereby restoring everyday confidence and providing more freedom in near vision.
As a result of these announcements, the company's shares have moved 6.8% on the market, and are now trading at a price of $44.89. For the full picture, make sure to review LENZ Therapeutics's 8-K report.
